Skip to main content
NCBI home page
Saudi Pharmaceutical Journal : SPJ logoLink to Saudi Pharmaceutical Journal : SPJ
. 2018 Feb 2;26(4):568–577. doi: 10.1016/j.jsps.2018.01.016

Synthesis and antibacterial activity of new (2,4-dioxothiazolidin-5-yl/ylidene)acetic acid derivatives with thiazolidine-2,4-dione, rhodanine and 2-thiohydantoin moieties

Nazar Trotsko a,⁎, Urszula Kosikowska b, Agata Paneth a, Monika Wujec a, Anna Malm b
PMCID: PMC5961620  PMID: 29844729

Abstract

A series of new (2,4-dioxothiazolidin-5-yl/ylidene)acetic acid derivatives with thiazolidine-2,4-dione, rhodanine and 2-thiohydantoin moiety (28–65) were synthesized by the reaction of (2,4-dioxothiazolidin-5-yl/ylidene)acetic acid chlorides with 5-(hydroxybenzylidene) thiazolidine-2,4-dione, rhodanine and 2-thiohydantoin derivatives. Obtained compounds (28–65) were tested on reference strains of Gram-positive bacteria and ones of the Gram-negative bacteria. The antibacterial activity of target compounds was determined by broth microdilution method. These derivatives showed antibacterial activity generally against Gram-positive bacterial strains. Most active compounds possess MIC = 3.91 mg/L. Our results suggest that presence of electron-withdrawing substituent at phenyl ring is favorable while geometry of molecule does not play important role in antibacterial response. It was confirmed the lack of direct influence of substitution pattern at phenyl ring on antibacterial activity of closely related compounds of series 1–3. The antibacterial activity of some compounds was similar or higher than the activity of commonly used reference drugs such as oxacillin and cefuroxime.

Keywords: Thiazolidine-2,4-dione; Rhodanine; 2-Thiohydantoin; Antibacterial activity

1. Introduction

The increasing resistance of bacteria to currently available antibiotics is an extremely serious problem in the treatment of infections. In the world, the emergence of bacteria with multiple genes for resistance has been reported, which may result in insensitivity to all available classes of antibiotics. Therefore, search of new antibacterial agents and investigation of new targets for antimicrobial drugs is an alternative to existing antimicrobial drugs (Trojanowski et al., 2014).

Thiazolidine-2,4-diones is a well-known class of biologically active compounds due to the group of antidiabetic drugs (Pioglitazone, Rosiglitazone etc.). Besides, the thiazolidine-2,4-dione is the ring with wide application as biologically active substances. It posses a broad spectrum of biological activity, including antibacterial (Heerding et al., 2003, Ibrahim et al., 2011, Liu et al., 2011, Bozdağ-Dündar et al., 2007, Aneja et al., 2011, Purohit et al., 2012, Desai et al., 2014a, Desai et al., 2014b, Shaikh et al., 2013, Trotsko et al., 2017), anticancer (Liu et al., 2010, Patil et al., 2010, Salamone et al., 2012), anti-inflammatory (Koppireddi et al., 2013, Barros et al., 2010), antifungal (Tuncbilek and Altanlar, 2006, Marc et al., 2017), antioxidant (Jeong et al., 2004).

One of the directions of the search for new bioactive compounds used in medicinal chemistry is combination two biologically active heterocyclic systems into single molecule. It is known that the combination of different pharmacophore or bioactive fragments with different mechanisms of the action often showed synergistic effects (Asati et al., 2014).

Such bioactive fragment may be a thiazolidine-2,4-dione and it structural analogues: rhodanine (2-thioxothiazolidine-4-one) and 2-thiohydantoin (2-thioxoimidazolidine-4-one) due to their broad spectrum of biological activity (anticancer (Moorthy et al., 2010, Min et al., 2013, Wu et al., 2015), anti-inflammatory (Cutshall et al., 2005, Irvine et al., 2008), anticonvulsant (Gangadhar et al., 2013), antiviral (Rajamaki et al., 2009, Jiang et al., 2011), antifungal (Sortino et al., 2007, Chauhan et al., 2012), particularly antibacterial activity (Zvarec et al., 2012, Song et al., 2014, Miao et al., 2013, Villain-Guillot et al., 2007, Hardej et al., 2010, Zheng et al., 2012, El Hady, 2012).

The aim of the present research was to synthesize new thiazolidine-2,4-dione derivatives modified in position 5 by 5-benzylidene derivatives of thiazolidine-2,4-dione and it structural analogues 5-benzylidene derivatives of rhodanine and 2-thiohydantoin and to evaluate in vitro their potential as antibacterial agents.

2. Experimental

2.1. Materials and methods

Melting points were determined by using Fischer-Johns apparatus (Fisher Scientific, Schwerte, Germany) and are uncorrected. The 1H NMR and 13C NMR spectra were recorded by a Bruker Avance 300 MHz instrument using DMSO-d6 as solvent and TMS as an internal standard. Chemical shifts were expressed as δ (ppm). The purity of the compounds was checked by TLC on plates with silica gel Si 60 F254, produced by Merck Co. (Darmstadt, Germany). Elemental analyses were performed by AMZ 851 CHX analyser and the results were within ±0.4% of the theoretical value.

2.2. General method for the synthesis of (2,4-dioxo-1,3-thiazolidin-5-yl/ylidene)acetate derivatives (28-65)

The solution of 0.01 mol acid chloride (3, 4) in 3 mL of anhydrous dioxane was added to a solution of 0.01 mol of corresponding 5-benzylidene derivatives of thiazolidine-2,4-dione (8–14), rhodanine (15–21) or 2-thiohydantoin (22–27) in 5 mL anhydrous pyridine. After 2 h, water was added and the mixture was acidified of diluted hydrochloric acid solution to pH = 3–4 and left at room temperature for 24 h. The precipitate was filtered off and then crystallized from n-butanol. For the compounds 50, 51, 57 and 58 mixture of DMF:water (2:1) was used as the solvent for crystallization.

2.2.1. 2-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (28)

Yield 74%, mp = 232–234 °C. 1H NMR δ (ppm) (DMSO-d6): 3.51–3.54 m (2H, CH—CH2); 4.85 dd (1H, CH—CH2, J = 5.4, 6.7 Hz); 7.31 d, 7.42–7.59 m (4H, C6H4, J = 8.1 Hz); 7.67 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.19 s, 12.70 s (2H, 2NH, thiazolidine). 13C NMR δ (ppm) (DMSO-d6): 36.3; 46.7; 123.8; 125.1; 126.5; 127.3; 127.6; 128.9; 132.1; 149.5; 167.4; 168.2; 169.4; 172.5; 175.8. Anal. calc. for C15H10N2O6S2 (%): C 47.61; H 2.66; N 7.40. Found: C 47.49; H 2.60; N 7.36.

2.2.2. 3-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (29)

Yield 77%, mp = 238–240 °C. CAS Registry Number: 938,870-16-7. 1H NMR δ (ppm) (DMSO-d6): 3.44–3.47 m (2H, CH—CH2); 4.86 dd (1H, CH—CH2, J = 5.3, 7.0 Hz); 7.25–7.38 m, 7.51–7.63 m (4H, C6H4); 7.80 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.32 bs (2H, 2NH, thiazolidine). 13C NMR δ (ppm) (DMSO-d6): 36.4; 46.8; 123.1; 124.0; 125.5; 128.2; 130.9; 131.1; 135.1; 151.0; 167.7; 168.2; 169.5; 172.6; 175.9. Anal. calc. for C15H10N2O6S2 (%): C 47.61; H 2.66; N 7.40. Found: C 47.29; H 2.65; N 7.34.

2.2.3. 4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (30)

Yield 73%, mp = 248–250 °C. CAS Registry Number: 938,740-39-7. 1H NMR δ (ppm) (DMSO-d6): 3.44–3.47 m (2H, CH—CH2); 4.84 dd (1H, CH—CH2, J = 5.1, 7.0 Hz); 7.30 d, 7.66 d (4H, 4-O—C6H4, J = 8.7 Hz); 7.81 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.24 s, 12.60 s (2H, 2NH, thiazolidine). 13C NMR δ (ppm) (DMSO-d6): 36.4; 46.8; 123.1; 124.2; 131.3; 131.5; 131.9; 151.7; 167.8; 168.3; 169.4; 172.6; 175.9. Anal. calc. for C15H10N2O6S2 (%): C 47.61; H 2.66; N 7.40. Found: C 47.55; H 2.70; N 7.38.

2.2.4. 4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-2-methoxyphenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (31)

Yield 86%, mp = 230–233 °C. CAS Registry Number: 938,895-02-4. 1H NMR δ (ppm) (DMSO-d6): 3.42–3.44 m (2H, CH—CH2); 3.82 s (3H, OCH3); 4.83 dd (1H, CH—CH2, J = 5.3, 6.8 Hz); 7.17 dd, 7.26 d, 7.38 d (3H, C6H3, J = 1.8, 8.4 Hz); 7.80 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.35 bs (2H, 2NH, thiazolidine). 13C NMR δ (ppm) (DMSO-d6): 36.1; 46.9; 56.5; 115.2; 122.5; 124.0; 124.4; 131.6; 132.8; 140.7; 151.5; 167.8; 168.3; 168.8; 172.7; 175.8. Anal. calc. for C16H12N2O7S2 (%): C 47.06; H 2.96; N 6.86. Found: C 47.03; H 2.92; N 6.83.

2.2.5. 4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-2-ethoxyphenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (32)

Yield 61%, mp = 238–240 °C. CAS Registry Number: 938,740-47-7. 1H NMR δ (ppm) (DMSO-d6): 1.32 t (3H, OCH2CH3, J = 7.0 Hz); 3.42 d (2H, CH—CH2, J = 6.0 Hz); 4.05 q (2H, OCH2CH3, J = 7.0 Hz); 4.84 t (1H, CH—CH2, J = 6.0 Hz); 7.16–7.36 m (3H, C6H3); 7.79 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.16 s, 12.57 s (2H, 2NH, thiazolidine). 13C NMR δ (ppm) (DMSO-d6): 14.8; 35.9; 46.7; 64.7; 115.9; 122.5; 123.9; 124.4; 131.6; 132.7; 140.9; 150.7; 167.7; 168.2; 168.6; 172.6; 175.7. Anal. calc. for C17H14N2O7S2 (%): C 48.34; H 3.34; N 6.63. Found: C 48.25; H 3.33; N 6.60.

2.2.6. 2-chloro-4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (33)

Yield 80%, mp = 234–236 °C. 1H NMR δ (ppm) (DMSO-d6): 3.51–3.54 m (2H, CH—CH2); 4.86 dd (1H, CH—CH2, J = 5.3, 6.7 Hz); 7.47 d, 7.59 dd, 7.86 d (3H, C6H3, J = 2.0, 8.5 Hz); 7.80 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.16 s, 12.68 s (2H, 2NH, thiazolidine). 13C NMR δ (ppm) (DMSO-d6): 36.0; 46.6; 125.4; 126.0; 127.1; 129.6; 129.8; 132.3; 133.4; 147.5; 167.5; 167.9; 168.6; 172.5; 175.6. Anal. calc. for C15H9ClN2O6S2 (%): C 43.64; H 2.20; N 6.79. Found: C 43.66; H 2.18; N 6.77.

2.2.7. 2-bromo-4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (34)

Yield 82%, mp = 243–245 °C. 1H NMR δ (ppm) (DMSO-d6): 3.51–3.53 m (2H, CH—CH2); 4.87 dd (1H, CH—CH2, J = 5.5, 6.5 Hz); 7.46 d, 7.64 dd, 7.99 d (3H, C6H3, J = 2.1, 8.4 Hz); 7.79 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.34 bs (2H, 2NH). 13C NMR δ (ppm) (DMSO-d6): 36.2; 46.6; 116.8; 125.3; 126.2; 129.6; 130.1; 133.8; 135.4; 148.8; 167.8; 168.1; 168.7; 172.5; 175.7. Anal. calc. for C15H9BrN2O6S2 (%): C 39.40; H 1.98; N 6.13. Found: C 39.31; H 1.94; N 6.11.

2.2.8. 2-[(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (35)

Yield 73%, mp = 212–214 °C. 1H NMR δ (ppm) (DMSO-d6): 3.52–3.55 m (2H, CH—CH2); 4.87 t (1H, CH—CH2, J = 6.6 Hz); 7.31–7.35 m, 7.47–7.59 m (5H, C6H4—CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.14 s (1H, NH, thiazolidine), 13.88 s (1H, NH, rhodanine). 13C NMR δ (ppm) (DMSO-d6): 36.4; 46.7; 124.0; 124.7; 126.4; 127.7; 129.1; 129.3; 132.5; 149.7; 169.4; 169.7; 172.5; 175.8; 196.1. Anal. calc. for C15H10N2O5S3 (%): C 45.68; H 2.56; N 7.10. Found: C 45.61; H 2.55; N 7.02.

2.2.9. 3-[(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (36)

Yield 74%, mp = 207–209 °C. CAS Registry Number: 938,740-53-5. 1H NMR δ (ppm) (DMSO-d6): 3.45–3.48 m (2H, CH—CH2); 4.85 dd (1H, CH-CH2, J = 5.6, 6.8 Hz); 7.26–7.39 m, 7.51–7.61 m (4H, C6H4); 7.65 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.16 s (1H, NH, thiazolidine), 13.89 s (1H, NH, rhodanine). 13C NMR δ (ppm) (DMSO-d6): 36.5; 46.8; 123.5; 124.4; 127.4; 128.7; 130.8; 131.2; 135.0; 151.1; 169.5; 169.8; 172.6; 175.9; 196.0. Anal. calc. for C15H10N2O5S3 (%): C 45.68; H 2.56; N 7.10. Found: C 45.59; H 2.53; N 7.11.

2.2.10. 4-[(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (37)

Yield 76%, mp = 236–238 °C. CAS Registry Number: 924,860-04-8. 1H NMR δ (ppm) (DMSO-d6): 3.44–3.47 m (2H, CH—CH2); 4.85 dd (1H, CH—CH2, J = 5.2, 7.0 Hz); 7.31 d, 7.67 d (4H, 4-O—C6H4, J = 8.7 Hz); 7.65 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.17 s (1H, NH, thiazolidine), 13.80 s (1H, NH, rhodanine). 13C NMR δ (ppm) (DMSO-d6): 36.4; 46.8; 123.3; 126.1; 130.9; 131.5; 132.4; 151.9; 169.3; 170.1; 172.6; 175.9; 196.2. Anal. calc. for C15H10N2O5S3 (%): C 45.68; H 2.56; N 7.10. Found: C 45.62; H 2.49; N 7.03.

2.2.11. 2-methoxy-4-[(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (38)

Yield 92%, mp = 242–243 °C. CAS Registry Number: 938,740-45-5. 1H NMR δ (ppm) (DMSO-d6): 3.42–3.44 m (2H, CH-CH2); 3.83 s (3H, OCH3); 4.83 dd (1H, CH—CH2, J = 5.3, 6.8 Hz); 7.18 dd, 7.27 d, 7.38 d (3H, C6H3, J = 1.8, 8.4 Hz); 7.65 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.13 s (1H, NH, thiazolidine), 13.85 s (1H, NH, rhodanine). 13C NMR δ (ppm) (DMSO-d6): 36.0; 46.8; 56.5; 115.5; 123.1; 124.2; 126.6; 131.2; 132.8; 140.9; 151.6; 168.7; 170.2; 172.6; 175.7; 196.3. Anal. calc. for C16H12N2O6S3 (%): C 45.27; H 2.85; N 6.60. Found: C 45.29; H 2.82; N 6.61.

2.2.12. 2-ethoxy-4-[(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (39)

Yield 85%, mp = 236–238 °C. CAS Registry Number: 938,895-04-6. 1H NMR δ (ppm) (DMSO-d6): 1.33 t (3H, OCH2CH3, J = 6.5 Hz); 3.42 d (2H, CH—CH2, J = 5.75 Hz); 4.07 q (2H, OCH2CH3, J = 6.5 Hz); 4.84 t (1H, CH—CH2, J = 5.75 Hz); 7.17 dd, 7.27 d, 7.36 d (3H, C6H3, J = 1.8, 8.4 Hz); 7.65 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.12 s (1H, NH, thiazolidine), 13.81 s (1H, NH, rhodanine). 13C NMR δ (ppm) (DMSO-d6): 14.9; 35.9; 46.8; 64.8; 116.2; 123.1; 124.1; 126.4; 131.4; 132.7; 141.3; 150.8; 168.6; 169.9; 172.6; 175.7; 196.1. Anal. calc. for C17H14N2O6S3 (%): C 46.57; H 3.22; N 6.39. Found: C 46.61; H 3.18; N 6.37.

2.2.13. 2-chloro-4-[(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (40)

Yield 81%, mp = 228–231 °C. 1H NMR δ (ppm) (DMSO-d6): 3.52–3.55 m (2H, CH—CH2); 4.87 dd (1H, CH—CH2, J = 5.2, 6.9 Hz); 7.49 d, 7.59 dd, 7.89 d (3H, C6H3, J = 2.1, 8.4 Hz); 7.65 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.17 s (1H, NH, thiazolidine), 13.92 s (1H, NH, rhodanine). 13C NMR δ (ppm) (DMSO-d6): 36.1; 46.6; 125.5; 127.2; 128.1; 129.4; 130.0; 132.8; 133.4; 147.7; 168.6; 170.2; 172.5; 175.7; 195.9. Anal. calc. for C15H9ClN2O5S3 (%): C 42.01; H 2.12; N 6.53. Found: C 41.83; H 2.01; N 6.55.

2.2.14. 2-bromo-4-[(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (41)

Yield 79%, mp = 225–226 °C. 1H NMR δ (ppm) (DMSO-d6): 3.51 d (2H, CH—CH2, J = 5.75 Hz); 4.89 t (1H, CH—CH2, J = 5.75 Hz); 7.46 d, 7.62–7.66 m, 8.01 d (4H, C6H3—CH Created by potrace 1.16, written by Peter Selinger 2001-2019 , J = 2.0, 8.5 Hz); 12.17 s (1H, NH, thiazolidine), 13.78 s (1H, NH, rhodanine). 13C NMR δ (ppm) (DMSO-d6): 36.3; 46.6; 117.0; 125.4; 128.0; 129.7; 130.5; 133.7; 135.9; 149.4; 168.6; 169.9; 172.5; 175.7; 195.9. Anal. calc. for C15H9BrN2O5S3 (%): C 38.06; H 1.92; N 5.92. Found: C 38.08; H 1.91; N 5.91.

2.2.15. 2-[(5-oxo-2-thioxoimidazolidin-4-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (42)

Yield 76%, mp = 228–230 °C. 1H NMR δ (ppm) (DMSO-d6): 3.46 d (2H, CH-CH2, J = 5.0 Hz); 4.85 t (1H, CH-CH2, J = 5.0 Hz); 6.34 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 7.20–7.50 m, 7.79–7.82 m (4H, C6H4); 12.12 s, 12.18 s, 12.44 s (3H, 3NH). 13C NMR δ (ppm) (DMSO-d6): 36.3; 46.7; 104.3; 123.1; 125.7; 127.0; 130.1; 130.8; 130.9; 149.0; 165.8; 169.4; 172.5; 175.8; 180.0. Anal. calc. for C15H11N3O5S2 (%): C 47.74; H 2.94; N 11.13. Found: C 47.63; H 2.82; N 11.04.

2.2.16. 3-[(5-oxo-2-thioxoimidazolidin-4-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (43)

Yield 75%, mp = 238–240 °C. 1H NMR δ (ppm) (DMSO-d6): 3.44–3.46 m (2H, CH—CH2); 4.84 dd (1H, CH—CH2, J = 5.3, 6.7 Hz); 6.48 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 7.14–7.17 m, 7.45–7.65 m (4H, C6H4); 12.20 bs, 12.44 s (3H, 3NH). 13C NMR δ (ppm) (DMSO-d6): 36.4; 46.8; 110.5; 122.9; 123.0; 128.6; 128.8; 130.4; 134.4; 150.8; 166.2; 169.5; 172.7; 175.9; 180.0. Anal. calc. for C15H11N3O5S2 (%): C 47.74; H 2.94; N 11.13. Found: C 47.80; H 2.89; N 11.11.

2.2.17. 4-[(5-oxo-2-thioxoimidazolidin-4-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (44)

Yield 72%, mp = 253–255 °C. 1H NMR δ (ppm) (DMSO-d6): 3.42–3.45 m (2H, CH—CH2); 4.84 dd (1H, CH—CH2, J = 5.2, 7.0 Hz); 6.50 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 7.17 d, 7.79 d (4H, 4-O—C6H4, J = 8.7 Hz); 12.18 s, 12.26 s, 12.41 s (3H, 3xNH). 13C NMR δ (ppm) (DMSO-d6): 36.5; 46.9; 110.9; 113.4; 123.8; 128.3; 130.8; 151.0; 166.2; 169.4; 172.7; 176.0; 179.8. Anal. calc. for C15H11N3O5S2 (%): C 47.74; H 2.94; N 11.13. Found: C 47.57; H 2.79; N 11.16.

2.2.18. 2-methoxy-4-[(5-oxo-2-thioxoimidazolidin-4-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (45)

Yield 81%, mp = 238–244 °C. 1H NMR δ (ppm) (DMSO-d6): 3.41–3.43 m (2H, CH—CH2); 3.86 s (3H, OCH3); 4.83 dd (1H, CH—CH2, J = 5.4, 6.6 Hz); 6.50 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 7.13 d, 7.35–7.39 m (3H, C6H3, J = 8.1 Hz); 12.24 bs, 12.41 s (3H, 3NH). 13C NMR δ (ppm) (DMSO-d6): 36.1; 46.9; 56.6; 111.4; 123.4; 123.6; 128.3; 132.1; 140.1; 151.2; 166.2; 168.8; 172.7; 175.8; 179.8. Anal. calc. for C16H13N3O6S2 (%): C 47.17; H 3.22; N 10.31. Found: C 46.99; H 3.17; N 10.34.

2.2.19. 2-ethoxy-4-[(5-oxo-2-thioxoimidazolidin-4-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (46)

Yield 65%, mp = 242–244 °C. 1H NMR δ (ppm) (DMSO-d6): 1.31 t (3H, OCH2CH3, J = 6.9 Hz); 3.41 d (2H, CH-CH2, J = 6.0 Hz); 4.11 q (2H, OCH2CH3, J = 6.9 Hz); 4.84 t (1H, CH-CH2, J = 6.0 Hz); 6.48 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 7.13–7.37 m (3H, C6H3); 12.13 s, 12.23 s, 12.41 s (3H, 3NH). 13C NMR δ (ppm) (DMSO-d6): 15.0; 36.3; 46.9; 64.8; 124.2; 125.6; 128.2; 132.0; 140.4; 147.4; 149.4; 150.5; 166.2; 168.7; 172.6; 175.8; 179.8. Anal. calc. for C17H15N3O6S2 (%): C 48.45; H 3.59; N 9.97. Found: C 48.55; H 3.61; N 9.93.

2.2.20. 2-bromo-4-[(5-oxo-2-thioxoimidazolidin-4-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-yl)acetate (47)

Yield 82%, mp = 258–260 °C. 1H NMR δ (ppm) (DMSO-d6): 3.49 d (2H, CH—CH2, J = 6.6 Hz); 4.88 t (1H, CH—CH2, J = 6.6 Hz); 6.47 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 7.32 d, 7.75 dd, 8.11 d (3H, C6H3, J = 2.1, 8.4 Hz); 12.18 s, 12.34 s, 12.46 s (3H, 3NH). 13C NMR δ (ppm) (DMSO-d6): 36.3; 46.7; 109.1; 116.5; 124.6; 129.2; 131.4; 133.0; 134.2; 148.1; 166.1; 168.7; 172.6; 175.7; 180.1. Anal. calc. for C15H10BrN3O5S2 (%): C 39.48; H 2.21; N 9.21. Found: C 39.38; H 2.03; N 9.18.

2.2.21. 2-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (48)

Yield 78%, mp = 267–269 °C. 1H NMR δ (ppm) (DMSO-d6): 7.17 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.43–7.62 m (4H, C6H4); 7.67 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.78 bs (2H, 2NH). 13C NMR δ (ppm) (DMSO-d6): 115.9; 123.9; 124.6; 126.1; 127.3; 127.9; 128.9; 132.2; 146.4; 149.3; 164.1; 166.6; 167.5; 168.1; 169.3. Anal. calc. for C15H8N2O6S2 (%): C 47.87; H 2.14; N 7.44. Found: C 47.92; H 2.11; N 7.34.

2.2.22. 3-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (49)

Yield 84%, mp = 268–270 °C. CAS Registry Number: 938,895-12-6. 1H NMR δ (ppm) (DMSO-d6): 7.09 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.35–7.39 m, 7.49–7.66 m (4H, C6H4); 7.80 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.75 bs (2H, 2NH). 13C NMR δ (ppm) (DMSO-d6): 116.8; 123.3; 124.0; 125.5; 128.2; 131.0; 131.1; 135.2; 145.3; 150.8; 164.2; 166.4; 167.7; 168.2; 169.4. Anal. calc. for C15H8N2O6S2 (%): C 47.87; H 2.14; N 7.44. Found: C 48.01; H 2.10; N 7.40.

2.2.23. 4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (50)

Yield 82%, mp = 298–299 °C. CAS Registry Number: 938,894-98-5. 1H NMR δ (ppm) (DMSO-d6): 7.06 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.40 d, 7.67 d (4H, 4-O—C6H4, J = 8.7 Hz); 7.81 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.76 bs (2H, 2NH). 13C NMR δ (ppm) (DMSO-d6): 116.6; 123.0; 124.4; 131.2; 131.8; 131.9; 145.6; 151.5; 164.0; 166.5; 167.7; 168.2; 169.3. Anal. calc. for C15H8N2O6S2 (%): C 47.87; H 2.14; N 7.44. Found: C 47.67; H 1.99; N 7.36.

2.2.24. 4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-2-methoxyphenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (51)

Yield 86%, mp = 292 °C. CAS Registry Number: 938,740-43-3. 1H NMR δ (ppm) (DMSO-d6): 3.83 s (3H, OCH3); 7.08 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.19 dd, 7.36 d, 7.42 d (3H, C6H3, J = 1.8, 8.4 Hz); 7.82 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.75 bs (2H, 2NH). 13C NMR δ (ppm) (DMSO-d6): 56.6; 115.3; 115.7; 122.5; 124.1; 124.6; 131.6; 133.2; 140.3; 146.3; 151.4; 163.6; 166.5; 167.7; 168.2; 169.3. Anal. calc. for C16H10N2O7S2 (%): C 47.29; H 2.48; N 6.89. Found: C 47.38; H 2.50; N 6.83.

2.2.25. 4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-2-ethoxyphenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (52)

Yield 74%, mp = 262–264 °C. CAS Registry Number: 938,740-49-9. 1H NMR δ (ppm) (DMSO-d6): 1.27 t (3H, OCH2CH3, J = 6.9 Hz); 4.08 q (2H, OCH2CH3, J = 6.9 Hz); 7.09 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.21 dd, 7.38 d, 7.41 d (3H, C6H3, J = 1.8, 8.4 Hz); 7.81 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.77 bs (2H, 2NH). 13C NMR δ (ppm) (DMSO-d6): 14.9; 64.8; 115.8; 116.1; 122.5; 124.0; 124.5; 131.6; 133.1; 140.7; 146.1; 150.6; 163.5; 166.5; 167.7; 168.2; 169.3. Anal. calc. for C17H12N2O7S2 (%): C 48.57; H 2.88; N 6.66. Found: C 48.39; H 2.78; N 6.67.

2.2.26. 2-chloro-4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (53)

Yield 79%, mp = 280–282 °C. 1H NMR δ (ppm) (DMSO-d6): 7.14 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.62–7.63 m, 7.90 d (3H, C6H3, J = 1.25 Hz); 7.82 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.78 bs (2H, 2NH). 13C NMR δ (ppm) (DMSO-d6): 115.3; 125.4; 126.2; 127.0; 129.7; 129.8; 132.4; 133.8; 146.9; 147.3; 163.3; 166.2; 167.5; 167.9; 169.0. Anal. calc. for C15H7ClN2O6S2 (%): C 43.86; H 1.72; N 6.82. Found: C 43.77; H 1.68; N 6.79.

2.2.27. 2-bromo-4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (54)

Yield 83%, mp = 278–279 °C. 1H NMR δ (ppm) (DMSO-d6): 7.12 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.56 d, 7.65 dd, 8.01 d (3H, C6H3, J = 2.0, 8.5 Hz); 7.81 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 12.67 bs (2H, 2NH). 13C NMR δ (ppm) (DMSO-d6): 115.5; 116.7; 125.3; 126.1; 129.8; 130.3; 134.0; 135.4; 146.9; 148.7; 163.4; 166.3; 167.5; 168.0; 169.0. Anal. calc. for C15H7BrN2O6S2 (%): C 39.57; H 1.55; N 6.15. Found: C 39.62; H 1.59; N 6.09.

2.2.28. 2-[(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (55)

Yield 86%, mp = 240–242 °C. 1H NMR δ (ppm) (DMSO-d6): 7.19 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.44–7.67 m (5H, C6H4—CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 13.54 s (2H, 2NH). 13C NMR δ (ppm) (DMSO-d6): 116.1; 124.0; 124.1; 126.0; 128.1; 129.1; 129.4; 132.5; 146.2; 149.5; 164.1; 166.4; 169.2; 169.6; 196.0. Anal. calc. for C15H8N2O5S3 (%): C 45.91; H 2.05; N 7.14. Found: C 45.83; H 1.97; N 7.11.

2.2.29. 3-[(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (56)

Yield 84%, mp = 272–274 °C. CAS Registry Number: 938,816-44-5. 1H NMR δ (ppm) (DMSO-d6): 7.09 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.37–7.41 m, 7.50–7.66 m (5H, C6H4—CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 13.48 s (2H, 2NH). 13C NMR δ (ppm) (DMSO-d6): 116.9; 123.5; 124.2; 127.4; 128.8; 130.6; 131.2; 135.0; 145.2; 150.9; 164.2; 166.3; 169.3; 169.7; 196.0. Anal. calc. for C15H8N2O5S3 (%): C 45.91; H 2.05; N 7.14. Found: C 45.78; H 2.01; N 7.09.

2.2.30. 4-[(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (57)

Yield 87%, mp = 290–292 °C. CAS Registry Number: 938,740-41-1. 1H NMR δ (ppm) (DMSO-d6): 7.07 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.41 d, 7.69 d (4H, C6H4, J = 8.7 Hz); 7.68 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 13.51 bs (2H, 2NH). 13C NMR δ (ppm) (DMSO-d6): 116.6; 123.2; 126.3; 131.0; 131.7; 132.4; 145.5; 151.7; 164.0; 166.4; 169.3; 169.9; 196.1. Anal. calc. for C15H8N2O5S3 (%): C 45.91; H 2.05; N 7.14. Found: C 46.00; H 2.03; N 7.14.

2.2.31. 2-methoxy-4-[(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (58)

Yield 91%, mp = 276–278 °C. CAS Registry Number: 938,895-00-2. 1H NMR δ (ppm) (DMSO-d6): 3.84 s (3H, OCH3); 7.08 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.20 dd, 7.38 d, 7.42 d (3H, C6H3, J = 1.8, 8.4 Hz); 7.67 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 13.47 bs (2H, 2NH). 13C NMR δ (ppm) (DMSO-d6): 56.6; 115.5; 115.7; 123.1; 124.2; 126.7; 131.3; 133.1; 140.6; 146.3; 151.5; 163.5; 166.5; 169.3; 169.9; 196.1. Anal. calc. for C16H10N2O6S3 (%): C 45.49; H 2.39; N 6.63. Found: C 45.55; H 2.41; N 6.59.

2.2.32. 2-ethoxy-4-[(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (59)

Yield 84%, mp = 266–268 °C. CAS Registry Number: 938,816-38-7. 1H NMR δ (ppm) (DMSO-d6): 1.28 t (3H, OCH2CH3, J = 6.9 Hz); 4.10 q (2H, OCH2CH3, J = 6.9 Hz); 7.09 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.20 dd, 7.37–7.41 m (3H, C6H3, J = 1.8, 8.4 Hz); 7.67 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 13.49 bs (2H, 2NH). 13C NMR δ (ppm) (DMSO-d6): 14.9; 64.9; 115.8; 116.4; 123.2; 124.1; 126.5; 131.4; 133.0; 140.9; 146.1; 150.7; 163.5; 166.4; 169.3; 169.8; 196.0. Anal. calc. for C17H12N2O6S3 (%): C 46.78; H 2.77; N 6.42. Found: C 46.66; H 2.48; N 6.38.

2.2.33. 2-chloro-4-[(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (60)

Yield 85%, mp = 269–272 °C. 1H NMR δ (ppm) (DMSO-d6): 7.13 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.38 dd, 7.62–7.67 m (3H, C6H3, J = 2.1, 8.4 Hz); 7.56 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 13.61 bs (2H, 2NH). 13C NMR δ (ppm) (DMSO-d6): 117.9; 121.3; 123.2; 125.7; 127.1; 130.8; 131.4; 133.5; 142.7; 156.1; 166.6; 166.7; 169.8; 170.2; 195.8. Anal. calc. for C15H7ClN2O5S3 (%): C 42.21; H 1.65; N 6.56. Found: C 42.04; H 1.47; N 6.61.

2.2.34. 2-bromo-4-[(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (61)

Yield 86%, mp = 271–273 °C. 1H NMR δ (ppm) (DMSO-d6): 7.09 d, 7.41 dd, 7.79 d (3H, C6H3, J = 2.1, 8.4 Hz); 7.13 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.55 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 13.63 bs (2H, 2NH). 13C NMR δ (ppm) (DMSO-d6): 110.8; 117.6; 118.9; 123.1; 126.1; 131.3; 136.5; 142.6; 146.8; 157.1; 166.2; 166.7; 169.8; 170.2; 195.7. Anal. calc. for C15H7BrN2O5S3 (%): C 38.23; H 1.50; N 5.94. Found: C 38.40; H 1.51; N 5.83.

2.2.35. 2-[(5-oxo-2-thioxoimidazolidin-4-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (62)

Yield 78%, mp = 264–266 °C. 1H NMR δ (ppm) (DMSO-d6): 6.32 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 7.14 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.36–7.52 m, 7.81–7.89 m (4H, C6H4); 12.25 s, 12.44 s, 12.98 bs (3H, 3NH).

13C NMR δ (ppm) (DMSO-d6): 103.7; 116.0; 123.1; 125.5; 127.2; 127.4; 130.2; 130.9; 146.1; 148.8; 164.2; 166.0; 166.4; 169.3; 180.0. Anal. calc. for C15H9N3O5S2 (%): C 47.99; H 2.42; N 11.19. Found: C 47.81; H 2.34; N 11.21.

2.2.36. 3-[(5-oxo-2-thioxoimidazolidin-4-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (63)

Yield 76%, mp = 282–284 °C. 1H NMR δ (ppm) (DMSO-d6): 6.49 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 7.10 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.24–7.28 m, 7.50 t, 7.64–7.67 m (4H, C6H4, J = 9.6 Hz); 12.19 s, 12.44 s, 12.95 bs (3H, 3NH). 13C NMR δ (ppm) (DMSO-d6): 110.4; 116.5; 122.7; 122.9; 128.8; 129.1; 130.5; 134.4; 145.7; 150.7; 164.3; 166.2; 166.6; 169.5; 180.0. Anal. calc. for C15H9N3O5S2 (%): C 47.99; H 2.42; N 11.19. Found: C 47.84; H 2.39; N 11.17.

2.2.37. 2-ethoxy-4-[(5-oxo-2-thioxoimidazolidin-4-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (64)

Yield 65%, mp = 224–226 °C. 1H NMR δ (ppm) (DMSO-d6): 1.25 t (3H, OCH2CH3, J = 6.9 Hz); 4.11 q (2H, OCH2CH3, J = 6.9 Hz); 6.50 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 7.07 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.24–7.26 m, 7.38–7.42 m (3H, C6H3); 12.06 s, 12.25 s, 12.43 s (3H, 3NH). 13C NMR δ (ppm) (DMSO-d6): 15.0; 64.8; 115.9; 116.3; 123.5; 124.2; 125.5; 128.3; 132.3; 140.1; 145.9; 150.4; 163.7; 166.3; 166.5; 169.4; 179.9. Anal. calc. for C17H13N3O6S2 (%): C 48.68; H 3.12; N 10.02. Found: C 48.73; H 3.09; N 9.97.

2.2.38. 2-bromo-4-[(5-oxo-2-thioxoimidazolidin-4-ylidene)methyl]phenyl (2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate (65)

Yield 73%, mp = 276–278 °C. 1H NMR δ (ppm) (DMSO-d6):6.48 s (1H, CH Created by potrace 1.16, written by Peter Selinger 2001-2019 ); 7.12 s (1H, Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO); 7.44 d, 7.77 dd, 8.13 d (3H, C6H3, J = 2.1, 8.4 Hz); 12.17 s, 12.38 s, 12.47 s (3H, 3NH). 13C NMR δ (ppm) (DMSO-d6): 109.1; 115.6; 116.3; 124.5; 125.5; 129.2; 131.5; 133.2; 134.2; 146.7; 147.8; 163.4; 169.1; 172.5; 180.1. Anal. calc. for C15H8BrN3O5S2 (%): C 39.66; H 1.78; N 9.25. Found: C 39.70; H 1.82; N 9.26.

2.3. Microbiology tests

The following reference strains of bacteria from American Type Culture Collection (ATCC) were used in the study: Gram-positive bacteria (Staphylococcus aureus ATCC 25923, Staphylococcus aureus ATCC 6538, Staphylococcus epidermidis ATCC 12228, Bacillus subtilis ATCC 6633, Bacillus cereus ATCC 10876, Micrococcus luteus ATCC 10240) and Gram-negative bacteria (Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC 13883, Proteus mirabilis ATCC 12453, Pseudomonas aeruginosa ATCC 9027). Microbial suspensions were prepared in sterile 0.85% NaCl with an optical density of 0.5 McFarland standard – 150 × 106 CFU/mL (CFU - colony forming units).

All stock solutions of detected compounds were dissolved in dimethyl sulfoxide (DMSO) at final concentration with no inhibitory effect on the growth of bacteria (negative control). The medium with DMSO at the final concentration and without the tested compounds served as negative control. A ciprofloxacin and oxacillin were used as reference antimicrobials.

The tested compounds (28–65) antibacterial activity was assayed in two steps. Firstly, it was screened using the agar dilution method on the basis of the microbial growth inhibition. Preliminary antibacterial effect of all compounds was screened on the Petri plates with the Mueller-Hinton agar medium with the tested compounds at concentrations 1000 mg/L. Then the antibacterial activity of the selected compounds with inhibitory effect with 1000 mg/L concentration was determined by broth microdilution technique using 96-well microplates with series of twofold dilution of the tested compounds, as well as the ciprofloxacin and oxacillin in the range of final concentrations from 0.007 to 1000 mg/L, according to described earlier (Trotsko et al., 2012).

The activity was expressed as the minimal inhibitory concentration (MIC) of the compound that inhibits the visible growth of the bacteria. MIC was assayed spectrophotometrically by optical density determination (OD600) using a broth microdilution technique. The MBC (minimal bactericidal concentration), defined as the lowest concentration of each compound that resulted in >99.9% reduction in CFU of the initial inoculum, was also determined. MBC was determined by plating out the contents of wells (5 μL) that showed no visible growth of bacteria, onto Mueller-Hinton agar plates and incubating at 35 °C for 18 h. The compounds were classified as bacteriostatic when the MBC/MIC ratio was greater than or equal to 8 and bactericidal when the MBC/MIC ratio is less than or equal to 4 (Jones, 2006).

2.4. Computational part

Conformational search was performed using the RM1 semiempirical parametrization as implemented in HyperChem 8.0.3. (2007) and default convergence criteria.

3. Results and discussion

3.1. Chemistry

In the present research as a starting material were (2,4-dioxothiazolidin-5-yl)acetic acid (1) and (2,4-dioxothiazolidin-5-ylidene)acetic acid (2). The (2,4-dioxothiazolidin-5-yl)acetic acid was synthesized by the reaction of cyclocondensation of thiourea with maleic anhydride in presence of concentrated hydrochloric acid (Lesyk et al., 2001). (2,4-Dioxothiazolidin-5-ylidene)acetic (2) was prepared by the reaction of compound (1) with bromine in acetic acid medium (Deghenghi and Daneault, 1960). The acids (1, 2) by the reaction with thionyl chloride in anhydrous 1,4-dioxane medium were transformed into acid chlorides (3, 4). Scheme 1 illustrates reactions’ pathway.

Scheme 1.

Scheme 1

Open in a new tab

Synthesis of (2,4-dioxothiazolidin-5-yl/ylidene)acetic acid chlorides. Reagents and conditions: (a) HCl, reflux; (b) SOCl2, DMF, 1,4-dioxane, reflux 1 h; (c) Br2, CH3COOH, reflux.

Next step of synthesis was obtaining of 5-benzylidene derivatives of thiazolidine-2,4-dione, rhodanine and 2-thiohydantoin. These compounds (8–27) were synthesized by Knoevenagel condensation of thiazolidine-2,4-dione, rhodanine and 2-thiohydantoin with corresponding hydroxybenzaldehydes. The reactions are shown in Scheme 2.

Scheme 2.

Scheme 2

Open in a new tab

Synthesis of 5-benzylidene derivatives of thiazolidine-2,4-dione, rhodanine and 2-thiohydantoin. Reagents and conditions: (a) salicylaldehyde, sodium acetate and acetic acid, reflux; (b) 4-hydroxybenzaldehyde, vanillin, 3-ethoxy-4-hydroxybenzaldehyde, 3-chloro-4-hydroxybenzaldehyde or 3-bromo-4-hydroxybenzaldehyde, sodium acetate and acetic acid, reflux; (c) 3-hydroxybenzaldehyde, sodium acetate and acetic acid, reflux.

Final step of synthesis was a connection 5-benzylidene derivatives (8–27) with acid chlorides (3, 4). Target compounds 28–65 were prepared from acetic acid chlorides (3, 4) and series of hydroxybenzylidene derivatives of thiazolidine-2,4-dione, rhodanine and 2-thiohydantoin. Reaction was provided in anhydrous 1,4-dioxane medium in the presence of anhydrous pyridine. The synthesis of these compounds (28–65) was achieved through synthetic route outlined in Scheme 3.

Scheme 3.

Scheme 3

Open in a new tab

Synthesis of target compounds (28–65) 2-(2,4-dioxothiazolidin-5-yl/ylidene)acetic acids derivatives. Reagents and conditions: (a) pyridine, 1,4-dioxane, rt, after 2 h acidified of solution of hydrochloric acid.

The structure of target compounds (28–65) was confirmed by elemental analysis, 1H NMR and 13C NMR spectra.

The fragment CH2CH of compounds (28–47) that are derivatives of 2-(2,4-dioxothiazolidin-5-yl)acetic acid appeared on 1H NMR spectra as two multiplets in 3.41–3.61 and 4.83–4.97 ppm ranges. For the compounds 32, 39, 41, 42, 46 and 47 signals of protons of the fragment CH2CH were visible as doublet in 3.43–3.52 ppm and triplet in 4.84–4.91 ppm ranges.

The proton CH Created by potrace 1.16, written by Peter Selinger 2001-2019 benzylidene group appeared in the 7.55–7.87 ppm range as singlet. For the 2-thiohydantoin derivatives (42–47 and 62–65) proton of CH Created by potrace 1.16, written by Peter Selinger 2001-2019 group was visible at δ ∼6.34–6.56 ppm.

Protons signals of Created by potrace 1.16, written by Peter Selinger 2001-2019 CH—COO group of compounds 48–65 were visible as a singlet at 7.06–7.21 ppm range.

Protons of NH group of heterocyclic rings appeared in the spectra as singlet or broad singlet in the range 12.06–13.63 ppm. For the compounds (35–41) that are rhodanine derivatives, proton signal of NH group was observed at 13.78–13.92 ppm range.

The presence of all carbon atoms for compounds (28–65) is confirmed by 13C NMR spectra. For the compounds 28–47, that are derivatives of 2-(2,4-dioxothiazolidin-5-yl)acetic acid, carbon signal of all C Created by potrace 1.16, written by Peter Selinger 2001-2019 O groups appeared in the 167.4–176.0 ppm region. Signals of all C Created by potrace 1.16, written by Peter Selinger 2001-2019 O groups for the 2-(2,4-dioxothiazolidin-5-ylilidene)acetic acid derivatives 48–65 were visible at δ ∼163.3–169.3 ppm range. Signals of C Created by potrace 1.16, written by Peter Selinger 2001-2019 S groups of rhodanine ring (35–41 and 55–61) were observed at 195.7–196.3 ppm range but 2-thiohydantoin derivatives (42–47 and 62–65) signals of C Created by potrace 1.16, written by Peter Selinger 2001-2019 S groups appeared in the 179.8–180.1 ppm region.

The detailed results of 1H NMR and 13C NMR spectra are presented in the experimental part.

3.2. Antimicrobial activity

Using the agar broth dilution method, it was shown that most tested compounds inhibited the growth of one to several reference species of bacteria at 1000 mg/L concentration. Only 32, 46, 48–50 and 55 compounds had no activity against all the tested bacteria.

Next, the compounds with potential inhibitory effect against bacteria was determined using broth dilution method. The variable antibacterial in vitro activity against the growth of the tested reference species of Gram-positive bacteria was shown as both concentration and species dependent (Table 1). The tested derivatives had mainly bacteriostatic effect (MBC/MIC > 4) towards the sensitive bacteria.

Table 1.

The antibacterial activity of (2,4-dioxo-1,3-thiazolidin-5-yl/ylidene)acetate derivatives (28–65).

Compound Gram-positive bacteria
 Gram-negative bacteria
Sa ATCC 6538
 Sa ATCC 25,923
 Se ATCC 12,228
 Bs ATCC 6633
 Bc ATCC 10,876
 Ml ATCC 10,240
 Pm ATCC 12,453
MIC
mg/L
μM		 MBC
mg/L
μM		 MIC
mg/L
μM		 MBC
mg/L
μM		 MIC
mg/L
μM		 MBC
mg/L
μM		 MIC
mg/L
μM		 MBC
mg/L
μM		 MIC
mg/L
μM		 MBC
mg/L
μM		 MIC
mg/L
μM		 MBC
mg/L
μM		 MIC
mg/L
μM		 MBC
mg/L
μM
28 >1000
>2642.8		 nd
 >1000
>2.642.8		 nd
 >1000
>2642.8		 nd
 >1000
>2642.8		 nd
 >1000
>2642.8		 nd
 >1000
>2642.8		 nd
 1000
2642.8		 >1000
>2642.8
29 >1000
>2642.8		 nd
 >1000
>2642.8		 nd
 >1000
>2642.8		 nd
 >1000
>2642.8		 nd
 >1000
>2642.8		 nd
 >1000
>2642.8		 nd
 1000
2642.8		 1000
2642.8
30 >1000
>2642.8		 nd
 >1000
>2642.8		 nd
 >1000
>2642.8		 nd
 >1000
>2642.8		 nd
 >1000
>2642.8		 nd
 >1000
>2642.8		 nd
 500
1321.4		 >1000
>2642.8
31 125
306.1		 250
612.1		 250
612.1		 250
612.1		 15.63
38.3		 250
612.1		 250
612.1		 250
612.1		 62.5
153.8		 500
1224.3		 125
306.1		 500
1224.3		 >1000
>2448.5		 nd
33 125
302.8		 >1000
>2422.3		 125
302.8		 >1000
>2422.3		 125
302.8		 >1000
>2422.3		 62.5
151.4		 >1000
>2422.3		 3.91
9.5		 >1000
>2422.3		 125
302.8		 >1000
>2422.3		 >1000
>2422.3		 nd
34 3.91
8.6		 >1000
>2186.9		 250
546.7		 >1000
>2186.9		 7.81
17.1		 500
1093.4		 62.5
136.7		 500
1093.4		 31.25
68.3		 >1000
>2186.9		 250
546.7		 500
1093.4		 >1000
>2186.9		 nd
35 >1000
>2535.2		 nd >1000
>2535.2		 nd >1000
>2535.2		 nd >1000
>2535.2		 nd >1000
>2535.2		 nd >1000
>2535.2		 nd 125
316.9		 250
633.8
36 >1000
 > 2535.2		 nd >1000
 > 2535.2		 nd >1000
 > 2535.2		 nd >1000
 > 2535.2		 nd >1000
 > 2535.2		 nd >1000
 > 2535.2		 nd 500
1267.6		 >1000
 > 2535.2
37 >1000
>2535.2		 nd >1000
>2535.2		 nd >1000
>2535.2		 nd >1000
>2535.2		 nd >1000
>2535.2		 nd >1000
>2535.2		 nd 1000
2535.2		 >1000
>2535.2
38 62.5
147.2		 125
294.5		 125
294.5		 250
589.0		 250
589.0		 500
1177.9		 125
294.5		 500
1177.9		 62.5
147.2		 250
589.0		 125
294.5		 500
1177.9		 >1000
>2355.9		 nd
39 125
285.1		 >1000
>2280.5		 62.5
142.5		 >1000
>2280.5		 62.5
142.5		 >1000
>2280.5		 62.5
142.5		 >1000
>2280.5		 62.5
142.5		 >1000
>2280.5		 62.5
142.5		 >1000
>2280.5		 >1000
>2280.5		 nd
40 >1000
>2331.6		 nd >1000
>2331.6		 nd >1000
>2331.6		 nd >1000
>2331.6		 nd >1000
>2331.6		 nd >1000
>2331.6		 nd 1000
2331.6		 1000
2331.6
41 3.91
8.3		 1000
2112.6		 15.63
33.0		 500
1056.3		 15.63
33.0		 500
1056.3		 31.25
66.0		 125
264.1		 15.63
33.0		 >1000
>2112.6		 3.91
8.3		 250
528.2		 >1000
>2112.6		 nd
42 >1000
>2649.7		 nd >1000
>2649.7		 nd >1000
>2649.7		 nd >1000
>2649.7		 nd >1000
>2649.7		 nd >1000
>2649.7		 nd 500
1324.9		 1000
2649.7
43 250
662.4		 >1000
>2649.7		 500
1324.9		 >1000
>2649.7		 250
662.4		 >1000
>2649.7		 62.5
165.6		 1000
2649.7		 500
1324.9		 >1000
>2649.7		 125
331.2		 >1000
>2649.7		 >1000
>2649.7		 nd
44 >1000
>2649.7		 nd >1000
>2649.7		 nd >1000
>2649.7		 nd >1000
>2649.7		 nd >1000
>2649.7		 nd >1000
>2649.7		 nd 125
331.2		 >1000
>2649.7
45 >1000
>2454.5		 nd >1000
>2454.5		 nd >1000
>2454.5		 nd >1000
>2454.5		 nd >1000
>2454.5		 nd >1000
>2454.5		 nd 125
306.8		 >1000
>2454.5
47 7.81
17.1		 31.25
68.5		 1000
2191.6		 1000
2191.6		 31.25
68.5		 1000
2191.6		 3.91
8.6		 250
547.9		 31.25
68.5		 1000
2191.6		 250
547.9		 1000
2191.6		 >1000
>2191.6		 nd
51 250615.2 >1000
>2460.7		 500
1230.3		 >1000
>2460.7		 62.5
153.8		 >1000
>2460.7		 125
307.6		 >1000
>2460.7		 31.25
76.9		 1000
2460.7		 62.5
153.8		 >1000
>2460.7		 >1000
>2460.7		 nd
52 15.63
37.2		 125
297.3		 125
297.3		 >1000
 > 2378.6		 62.5
148.7		 >1000
 > 2378.6		 15.63
37.2		 >1000
 > 2378.6		 31.25
74.3		 >1000
 > 2378.6		 31.25
74.3		 >1000
 > 2378.6		 >1000
 > 2378.6		 nd
53 31.25
76.1		 >1000
>2434.2		 125
304.3		 1000
2434.2		 31.25
76.1		 1000
2434.2		 125
304.3		 500
1217.1		 125
304.3		 >1000
>2434.2		 125
304.3		 >1000
>2434.2		 >1000
>2434.2		 nd
54 62.5
137.3		 >1000
>2196.5		 31.25
68.6		 >1000
>2196.5		 7.81
17.2		 >1000
>2196.5		 125
274.6		 >1000
>2196.5		 31.25
68.6		 >1000
>2196.5		 31.25
68.6		 500
1098.3		 >1000
>2196.5		 nd
56 31.25
79.6		 1000
2548.2		 7.81
19.9		 1000
2548.2		 125
318.5		 500
1274.1		 250
637.1		 500
1274.1		 15.63
39.8		 500
1274.1		 15.63
39.8		 500
1274.1		 >1000
>2548.2		 nd
57 125
318.5		 >1000
>2548.2		 62.5
159.3		 >1000
>2548.2		 31.25
79.6		 >1000
>2548.2		 62.5
159.3		 >1000
>2548.2		 125
318.5		 >1000
>2548.2		 31.25
79.6		 >1000
>2548.2		 >1000
>2548.2		 nd
58 62.5
147.9		 250
591.8		 31.25
74.0		 500
1183.6		 15.63
37.0		 250
591.8		 31.25
74.0		 500
1183.6		 15.63
37.0		 500
1183.6		 15.63
37.0		 500
1183.6		 >1000
 > 2367.1		 nd
59 15.63
35.8		 1000
2291.0		 62.5
143.2		 >1000
>2291.0		 125
286.4		 1000
2291.0		 31.25
71.6		 1000
2291.0		 15.63
35.8		 >1000
>2291.0		 15.63
35.8		 >1000
>2291.0		 >1000
>2291.0		 nd
60 7.81
18.3		 500
1171.3		 62.5
146.4		 250
585.7		 31.25
73.2		 250
585.7		 250
585.7		 1000
2342.6		 31.25
73.2		 1000
2342.6		 250
585.7		 >1000
>2342.6		 >1000
>2342.6		 nd
61 31.25
66.3		 >1000
>2121.7		 62.5
132.6		 >1000
>2121.7		 125
265.2		 >1000
>2121.7		 62.5
132.6		 250
530.4		 62.5
132.6		 1000
2121.7		 125
265.2		 >1000
>2121.7		 >1000
 > 2121.7		 nd
62 >1000
>2664.0		 nd >1000
>2664.0		 nd >1000
>2664.0		 nd >1000
>2664.0		 nd >1000
>2664.0		 nd >1000
>2664.0		 nd 250
666.0		 >1000
>2664.0
63 >1000
>2664.0		 nd >1000
>2664.0		 nd >1000
>2664.0		 nd >1000
>2664.0		 nd >1000
>2664.0		 nd >1000
>2664.0		 nd 250
666.0		 >1000
>2664.0
64 31.25
74.5		 1000
2384.2		 500
1192.1		 >1000
>2384.2		 31.25
74.5		 >1000
>2384.2		 500
1192.1		 >1000
>2384.2		 62.5
149.0		 >1000
>2384.2		 15.63
37.3		 >1000
>2384.2		 >1000
>2384.2		 nd
65 1000
2201.3		 >1000
>2201.3		 1000
2201.3		 >1000
>2201.3		 500
1100.7		 >1000
>2201.3		 500
1100.7		 >1000
>2201.3		 500
1100.7		 >1000
>2201.3		 1000
2201.3		 500
1100.7		 >1000
>2201.3		 nd
Oxacillin 0.06
0.15		 0.06
0.15		 nd nd 0.12
0.3		 0.12
0.3		 0.06
0.15		 0.12
0.3		 62.5
155.7		 62.5
155.7		 0.98
2.4		 0.98
2.4		 0.24
0.6		 0.49
1.2
Ciprofloxacin 0.49
1.5		 0.49
1.5		 nd nd 0.49
1.5		 0.49
1.5		 0.015
0.05		 0.12
0.4		 0.12
0.4		 0.12
0.4		 0.98
3.0		 1.95
5.9		 0.015
0.05		 0.24
0.7
Cefuroximea nd nd 0.49
1.2		 nd 0.24
0.6		 nd 15.63
36.8		 nd 31.25
73.6		 nd 0.98
2.3		 nd nd nd
Open in a new tab

Abbreviations: Sa ATCC 25,923 - Staphylococcus aureus ATCC 25,923, Sa ATCC 6538 - Staphylococcus aureus ATCC 6538, Se ATCC 12,228 - Staphylococcus epidermidis ATCC 12,228, Bs 6633 - Bacillus subtilis ATCC 6633, Bc ATCC 10,876 – Bacillus cereus ATCC 10,876, Ml 10,240 - Micrococcus luteus ATCC 10,240, Pm ATCC 12,453- Proteus mirabilis ATCC 12,453; nd - not determined.

a

Data derived from Plech et al. (2013).

Among Gram-negative species only P. mirabilis ATCC 12453 had moderate sensitivity on 35, 44, 45 compounds with MIC = 125 mg/L, and on 62 and 63 compounds with MIC = 250 mg/L. None of the tested compound had inhibitory effect against the growth of Gram-negative E. coli, K. pneumoniae and P. aeruginosa reference species.

In the absence of detailed information about the molecular target, in order to identify the privileged scaffold for antibacterial activity among various thiazolidine-2,4-dione-based derivatives, we selected five compounds representing series of thiazolidine-2,4-dione-phenyl-thiazolidine-2,4-dione hybrids (series 1). As indicate from results collected in Table 1, the compound 30 was inactive against all tested Gram-positive bacteria. Adding electron-donating methoxy group to phenyl ring provided compound 31 with potent activity against S. epidermidis (MIC 15.63 mg/L) and mild to weak inhibitory activity against remaining Gram-positive bacteria (MICs range from 62.5 to 250 mg/L). Increasing the carbon chain from methyl to ethyl (compound 32) completely reduced the activity. In turn, the replacement of methoxy group in 31 with electron-withdrawing chloro group as in 33 improved the activity by twofold against S. aureus and fourfold against B. subtilis. Important to note, 33 inhibited the growth of B. cereus at MIC of 3.91 mg/L thereby indicating more effective action than those standard drugs oxacillin and cefuroxime. Finally, incorporation of bromo group within phenyl ring furnished compound 34 with the best activity among all compounds series 1. Indeed, as seen from results collected in Table 1, 34 exhibited antibacterial potency at MIC of 3.91 and 7.81 mg/L against S. aureus and S. epidermidis reference strains. Moreover, it had activity equipotent to that of oxacillin and cefuroxime against B. cereus. These results collectively suggest that the presence of electron-withdrawing substituent at phenyl ring is favorable while geometry of molecule does not play important role in antibacterial response. Indeed, as illustrated in Fig. 1 for representative model compounds, the superposition of the most stable conformers of active and inactive revealed only minor deviations.

Fig. 1.

Fig. 1

Open in a new tab

Superposition diagram of compounds active 34 and inactive 30 (left) and active 54 and inactive 50 (right). Remaining compounds within series 1, 4 and 5 share geometry of molecule very similar to that of compounds 34 and 30 while all compounds series 2 and 3 share geometry of molecule very similar to that of compounds 54 and 50.

Taking into consideration the results highlighted above, the next set of structures included adding double bond between thiazolidine-2,4-dione and ester core. Hence, compounds 50–54 (series 2) were synthesized. Within series 2 the best antibacterial response was noted both for compounds with electron-donating ethoxy group 52 and for ones with electron-withdrawing bromo group 54 with MICs in the range from 7.81 to 125 mg/L against all Gram-positive bacterial strains tested, following by 53 with MICs at 31.25 mg/L against S. aureus and S. epidermidis and 51 with MIC = 31.25 mg/L against B. cereus. Again, no antibacterial response was detected for compound without substitution at phenyl ring (50) suggesting that such core is not tolerated. The second important result of these studies is that geometry of molecule is not detrimental for activity; in spite of the fact that compounds of series 2 differ in the geometry of the molecule from the compounds of series 1, their activity is not uniquely favorable.

Subsequently, series 3, structurally very similar to that of series 2 was synthesized. The compounds were obtained by replacement thiazolidine-2,4-dione with rhodanine ring. Again, the observed trend in antibacterial activity cannot be not easily explain. In contrast to series 2, within this chemical series the best antibacterial response (MIC = 7.81 mg/L) was detected for compound with electron-withdrawing chloro substitution (60). However, the potent antibacterial effect for 60, even comparable to oxacillin and cefuroxime, was observed only against S. aureus and B. cereus; remaining Gram-positive bacterial strains were able to grow at high concentrations (MICs from 31.25 to 62.50 mg/L) or even were almost insensitive to 60 (MICs = 250 mg/L). In turn, compound 58 with electron-donating methoxy substitution showed fourfold better activity than oxacillin and twofold better than cefuroxime against B. cereus. The same level of its activity with MIC at 15.63 mg/L was also observed against M. luteus. In contrast to series 1, increasing the carbon chain from methyl to ethyl gave compound 59 with comparable activity to 58; MICs in the range from 15.63 to 62.5 mg/L. Surprisingly, for the first time antibacterial response was also observed for derivative with phenyl core, compound 57. Important to note, although activity of 57 was not impressive, MICs in the range from 31.25 to 125 mg/L, it was still comparable to these obtained for 61 with bromo substitution. This is very important result, because it further confirms the lack of direct influence of substitution pattern at phenyl ring on antibacterial activity of closely related compounds of series 1–3. Unfortunately, the results for series 4 exclude the direct relationship between geometry and antibacterial activity as well. Indeed, although two compounds of series 4 were inactive (37 and 40) and two other had only marginal activity (38 and 39; MICs at 62.5 mg/L or higher), this series still contains bromo derivative 41 ranked among the most potent antibacterial agents tested so far. It is important to note that also within series 1, that is structurally closely related to series 4, the best antibacterial activity was found also for bromo derivative 34.

Next, the rhodanine ring of series 4 was replacement with 2-thiohydantoin ring and compounds series 5 were obtained. Similar to the SAR with series 1 and 4, compound with bromo substitution 47 was effective against most of the Gram-positive strains tested with MICs in the range from 3.91 to 31.25 mg/L. Remaining compounds with this chemical series were inactive even at high concentration. A point worth highlighting is that adding double bond to compound 47 significantly reduced antibacterial activity of the compound 65 (MICs = 500–1000 mg/L), which is consistent with the results highlighted above.

Finally, in order to clearly exclude phenyl core from future research, two series of regioisomerics, series 6 with meta substitution and series 7 with ortho substitution were obtained and subsequently tested. As we expected, with the exception of 56 with MICs in the range from 7.81 to 15.63 mg/L against most of the tested Gram-positive bacteria and 43 with marginal activity, no antibacterial response was observed.

To the same conclusion are provided by the analysis of structure-activity relationships of studied compounds in terms of their micromolar concentrations.

4. Conclusions

A series of new thiazolidine-2,4-dione-phenyl-azoles hybrids were synthesized. These derivatives were assayed for antibacterial activity. Most tested compounds were shown antibacterial activity against Gram-positive bacteria. As a result of antibacterial evaluation our research showed that the presence of electron-withdrawing substituent at phenyl ring for thiazolidine-2,4-dione-phenyl-azoles hybrids is favorable while geometry of molecule does not play important role in antibacterial response. The second important result of these studies is that geometry of molecule is not detrimental for activity. Further confirmed the lack of direct influence of substitution pattern at phenyl ring on antibacterial activity of closely related compounds of series 1–3. Unfortunately, the results for series 4 exclude the direct relationship between geometry and antibacterial activity as well. The antibacterial activity of some compounds was similar or higher than the activity of commonly used reference drugs such as oxacillin and cefuroxime.

Conflict of interest

None.

Footnotes

Peer review under responsibility of King Saud University.

References

  1. Aneja D.K., Lohan P., Arora S., Sharma C., Aneja K.R., Prakash O. Synthesis of new pyrazolyl-2, 4-thiazolidinediones as antibacterial and antifungal agents. Org. Med. Chem. Lett. 2011;1:15. doi: 10.1186/2191-2858-1-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Asati V., Mahapatra D.K., Bharti S.K. Thiazolidine 2,4-diones as multi-targed scaffold in medicinal chemistry: Potential anticancer agents. Eur. J. Med. Chem. 2014;87:814–833. doi: 10.1016/j.ejmech.2014.10.025. [DOI] [PubMed] [Google Scholar]
  3. Barros C.D., Amato A.A., De Oliveira T.B., Iannini K.B.R., Da Silva A.L., Da Silva T.G., Leite E.S., Marcelo Zaldini Hernandes M.Z., De Lima M.C.A., Galdino S.L., Neves F.A.R., Pitta I.R. Synthesis and anti-inflammatory activity of new arylidene-thiazolidine-2,4-diones as PPARγ ligands. Bioorg. Med. Chem. 2010;18:3805–3811. doi: 10.1016/j.bmc.2010.04.045. [DOI] [PubMed] [Google Scholar]
  4. Bozdağ-Dündar O., Özgen Ö., Menteşe A., Altanlar N., Atlı O., Kendi E., Ertan R. Synthesis and antimicrobial activity of some new thiazolyl thiazolidine-2,4-dione derivatives. Bioorg. Med. Chem. 2007;15:6012–6017. doi: 10.1016/j.bmc.2007.06.049. [DOI] [PubMed] [Google Scholar]
  5. Chauhan K., Sharma M., Singh P., Kumar V., Shukla P.K., Siddiqi M.I., Chauhan P.M.S. Discovery of a new class of dithiocarbamates and rhodanine scaffold as potent antifungal agent: synthesis, biology and molecular docking. Med. Chem. Commun. 2012;3:1104–1110. [Google Scholar]
  6. Cutshall N.S., O'Day C., Prezhdo M. Rhodanine derivatives as inhibitors of JSP-1. Bioorg. Med. Chem. Lett. 2005;15:3374–3379. doi: 10.1016/j.bmcl.2005.05.034. [DOI] [PubMed] [Google Scholar]
  7. Deghenghi R., Daneault G. Orotic acid and its analogues: part II. On the alkaline rearrangement of 5-carboxymethylidenehydantoin. Can. J. Chem. 1960;38:1255–1260. [Google Scholar]
  8. Desai N.C., Satodiya H.M., Rajpara K.M., Joshi V.V., Bhatt K., Vaghani H.V. Synthesis and evaluation of N-substituted thiazolidine-2,4-dione containing pyrazole as potent antimicrobial agents. Anti-Infective Agents. 2014;12:85–94. [Google Scholar]
  9. Desai N.C., Satodiya H.M., Kotadiya G.M., Vaghani H.V. Synthesis and antibacterial and cytotoxic activities of new N-3 substituted thiazolidine-2,4-dione derivatives bearing the pyrazole moiety. Arch. Pharm. Chem. Life Sci. 2014;347:523–532. doi: 10.1002/ardp.201300466. [DOI] [PubMed] [Google Scholar]
  10. El Hady H.A. Syntheses and antimicrobial activity of some new thiohydantoin and thiazole derivatives. Der Pharma Chemica. 2012;4:2202–2207. [Google Scholar]
  11. Gangadhar S.P., Ramesh D.K., Mahajan S.K. Synthesis, characterisation and anticonvulsant activity of 3-substituted 2-thiohydantoin derivatives. Int. J. Res. Pharm. Chem. 2013;3:793–796. [Google Scholar]
  12. Hardej D., Ashby C.R., Khadtare N.S., Kulkarni S.S., Singh S., Talele T.T. The synthesis of phenylalanine-derived C5-substituted rhodanines and their activity against selected methicillin-resistant Staphylococcus aureus (MRSA) strains. Eur. J. Med. Chem. 2010;45:5827–5832. doi: 10.1016/j.ejmech.2010.09.045. [DOI] [PubMed] [Google Scholar]
  13. Heerding D.A., Christmann L.T., Clark T.J., Holmes D.J., Rittenhouse S.F., Takata D.T., Venslavsky J.W. New benzylidenethiazolidinediones as antibacterial agents. Bioorg. Med. Chem. Lett. 2003;13:3771–3773. doi: 10.1016/j.bmcl.2003.07.010. [DOI] [PubMed] [Google Scholar]
  14. HyperChem 8.0.3. HyperCube Inc., Gainsville, FL, USA, 2007.
  15. Ibrahim M.A., Abdel-Megid Abdel-Hamed M., El-Gohary N.M. A new approach for the synthesis of bioactive heteroaryl thiazolidine-2,4-diones. J. Braz. Chem. Soc. 2011;22:1130–1139. [Google Scholar]
  16. Irvine M.W., Patrick G.L., Kewney J., Hastings S.F., MacKenzie S.J. Rhodanine derivatives as novel inhibitors of PDE4. Bioorg. Med. Chem. Lett. 2008;18:2032–2037. doi: 10.1016/j.bmcl.2008.01.117. [DOI] [PubMed] [Google Scholar]
  17. Jeong T.-S., Kim J.-R., Kim K.S., Cho K.-H., Bae K.-H., Lee W.S. Inhibitory effects of multi-substituted benzylidenethiazolidine-2,4-diones on LDL oxidation. Bioorg. Med. Chem. 2004;12:4017–4023. doi: 10.1016/j.bmc.2004.06.001. [DOI] [PubMed] [Google Scholar]
  18. Jiang S., Tala S.R., Lu H., Abo-Dya N.E., Avan I., Gyanda K., Lu L., Katritzky A.R., Debnath A.K. Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 Fusion Inhibitors Targeting gp41. J. Med. Chem. 2011;54:572–579. doi: 10.1021/jm101014v. [DOI] [PubMed] [Google Scholar]
  19. Jones R.N. Microbiological features of vancomycin in the 21st century: Minimum inhibitory concentration creep, bactericidal/static activity and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin. Infect. Dis. 2006;42:S13–S24. doi: 10.1086/491710. [DOI] [PubMed] [Google Scholar]
  20. Koppireddi S., Komsani J.R., Avula S., Pombala S., Vasamsetti S., Kotamraju S., Yadla R. Novel 2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamides as antioxidant and/or anti-inflammatory compounds. Eur. J. Med. Chem. 2013;66:305–313. doi: 10.1016/j.ejmech.2013.06.005. [DOI] [PubMed] [Google Scholar]
  21. Lesyk R.B., Zimenkovsky B.S., Golota S.M., Leb'yak M.M. Synthesis of 2,4-dioxothiazolidine-5-acetic acid and its amides - perspective synthons for obtaining combinatorial libraries of biologically active substances. Farm. Zh. (Kiev) 2001;5:57–62. [Google Scholar]
  22. Liu X., Xie H., Luo C., Tong L., Wang Y., Peng T., Ding J., Jiang H., Li H. Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening. J. Med. Chem. 2010;53:2661–2665. doi: 10.1021/jm901798e. [DOI] [PubMed] [Google Scholar]
  23. Liu X.-F., Zheng C.-J., Sun L.-P., Liu X.-K., Piao H.-R. Synthesis of new chalcone derivatives bearing 2,4-thiazolidinedione and benzoic acid moieties as potential anti-bacterial agents. Eur. J. Med. Chem. 2011;46:3469–3473. doi: 10.1016/j.ejmech.2011.05.012. [DOI] [PubMed] [Google Scholar]
  24. Marc G., Ionuţ I., Pîrnău A., Vlase L., Vodnar D.C., Duma M., Tiperciuc B., Oniga O. Microvawe assisted synthesis of 3,5-disubstituted thiazolidine-2,4-diones with antifungal activity. Design, synthesis, virtual and in vitro antifungal screening. Farmacia. 2017;65:414–422. [Google Scholar]
  25. Miao J., Zheng C.-J., Sun L.-P., Song M.-X., Xu L.-L., Piao H.-R. Synthesis and potential antibacterial activity of new rhodanine-3-acetic acid derivatives. Med. Chem. Res. 2013;22:4125–4132. [Google Scholar]
  26. Min G., Lee S.K., Kim H.N., Han Y.M., Lee R.H., Jeong D.G., Han D.C., Kwon B.M. Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells. Bioorg. Med. Chem. Lett. 2013;23:3769–3774. doi: 10.1016/j.bmcl.2013.04.092. [DOI] [PubMed] [Google Scholar]
  27. Moorthy B.T., Ravi S., Srivastava M., Chiruvella K.K., Hemlal H., Joy O., Raghavan S.C. Novel rhodanine derivatives induce growth inhibition followed by apoptosis. Bioorg. Med. Chem. Lett. 2010;20:6297–6301. doi: 10.1016/j.bmcl.2010.08.084. [DOI] [PubMed] [Google Scholar]
  28. Patil V., Tilekar K., Mehendale-Munj S., Mohan R., Ramaa C.S. Synthesis and primary cytotoxicity evaluation of new 5-benzylidene-2,4-thiazolidinedione derivatives. Eur. J. Med. Chem. 2010;45:4539–4544. doi: 10.1016/j.ejmech.2010.07.014. [DOI] [PubMed] [Google Scholar]
  29. Plech T., Wujec M., Majewska M., Kosikowska U., Malm A. Microbiologically active Mannich bases derived from 1,2,4-triazoles. The effect of C-5 substituent on antibacterial activity. Med. Chem. Res. 2013;22:2531–2537. doi: 10.1007/s00044-012-0248-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Purohit S.S., Alman A., Shewale J. Synthesis & antimicrobial activity of a new series of 3, 5-disubstituted thiazolidine-2, 4-diones. Int. J. Pharm. Pharm. Sci. 2012;4(Suppl. 3):273–276. [Google Scholar]
  31. Rajamaki S., Innitzer A., Falciani C., Tintori C., Christ F., Witvrouw M., Debyser Z., Massa S., Botta M. Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 2009;19:3615–3618. doi: 10.1016/j.bmcl.2009.04.132. [DOI] [PubMed] [Google Scholar]
  32. Salamone S., Colin C., Grillier-Vuissoz I., Kuntz S., Mazerbourg S., Flament S., Martin H., Richert L., Chapleur Y., Boisbrun M. Synthesis of new troglitazone derivatives: Anti-proliferative activity in breast cancer cell lines and preliminary toxicological study. Eur. J. Med. Chem. 2012;51:206–215. doi: 10.1016/j.ejmech.2012.02.044. [DOI] [PubMed] [Google Scholar]
  33. Shaikh F.M., Patel N.B., Rajani D. Synthesis of new thiazolidine-2,4-dione derivatives and their antimicrobial and antitubercular activity. Indian J. Res. Pharm. Biotechnol. 2013;1:496–503. [Google Scholar]
  34. Song M.-X., Zheng C.-J., Deng X.-Q., Wei Z.-Y., Piao H.-R. The synthesis and antibacterial activities of N-carboxymethyl rhodanines. Med. Chem. 2014;4:441–448. [Google Scholar]
  35. Sortino M., Delgado P., Juárez S., Quiroga J., Abonía R., Insuasty B., Nogueras M., Rodero L., Garibotto F.M., Enriz R.D., Zacchino S.A. Synthesis and antifungal activity of (Z)-5-arylidenerhodanines. Bioorg. Med. Chem. 2007;15:484–494. doi: 10.1016/j.bmc.2006.09.038. [DOI] [PubMed] [Google Scholar]
  36. Trojanowski D., Skut P., Hołówka J., Szafran M.J. Searching for new antibiotics – inhibitors of bacterial chromosome replication. Postepy Hig. Med. Dosw. (online) 2014;68:701–714. doi: 10.5604/17322693.1106890. [DOI] [PubMed] [Google Scholar]
  37. Trotsko N., Król J., Siwek A., Wujec M., Kosikowska U., Malm A. Synthesis and antimicrobial evaluation of new 1-{[4-(4-halogenophenyl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetyl-4-substituted thiosemicarbazides and products of their cyclization. Heteroatom Chem. 2012;23:117–121. [Google Scholar]
  38. Trotsko N., Wujec M., Kosikowska U., Malm A. Synthesis of new (2,4-dioxothiazolidin-5-yl)acetic acid derivatives with piperazine and 1,2,4-triazole substitutes and their antimicrobial activity evaluation. Int. J. Med. Chem. Anal. 2017;7:41–47. [Google Scholar]
  39. Tuncbilek M., Altanlar N. Synthesis of new 3-(substituted phenacyl)-5-[3′-(4H-4-oxo-1-benzopyran-2-yl)-benzylidene]-2,4-thiazolidinediones and their antimicrobial activity. Arch. Pharm. 2006;339:213–216. doi: 10.1002/ardp.200500180. [DOI] [PubMed] [Google Scholar]
  40. Villain-Guillot P., Gualtieri M., Bastide L., Roquet F., Martinez J., Amblard M., Pugniere M., Leonetti J.P. Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms. J. Med. Chem. 2007;50:4195–4204. doi: 10.1021/jm0703183. [DOI] [PubMed] [Google Scholar]
  41. Wu F., Jiang H., Zheng B., Kogiso M., Yao Y., Zhou C., Li X.-N., Song Y. Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-thiohydantoin compounds. J. Med. Chem. 2015;58:6899–6908. doi: 10.1021/acs.jmedchem.5b00684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Zheng C.J., Song M.X., Sun L.P., Wu Y., Hong L., Piao H.R. Synthesis and biological evaluation of 5-aryloxypyrazole derivatives bearing a rhodanine-3-aromatic acid as potential antimicrobial agents. Bioorg. Med. Chem. Lett. 2012;22:7024–7028. doi: 10.1016/j.bmcl.2012.09.107. [DOI] [PubMed] [Google Scholar]
  43. Zvarec O., Polyak S.W., Tieu W., Kuan K., Dai H., Pedersen D.S., Morona R., Zhang L., Booker G.W., Abell A.D. 5-Benzylidenerhodanine and 5-benzylidene-2,4-thiazolidinedione based antibacterials. Bioorg. Med. Chem. Lett. 2012;22:2720–2722. doi: 10.1016/j.bmcl.2012.02.100. [DOI] [PubMed] [Google Scholar]

Articles from Saudi Pharmaceutical Journal : SPJ are provided here courtesy of Springer

RESOURCES